When a truckload of stocker calves rolls into an Oklahoma backgrounding yard, the standard playbook is to dose nearly every animal with antibiotics on arrival. This practice is called metaphylaxis. The disease state in question is bovine respiratory disease, the leading cause of illness and death in feedlot cattle. The patient population is the roughly 25 million head that move through U.S. feedlots each year.
Advanced Animal Diagnostics, a Morrisville, North Carolina biotech founded in 2001, is trying to change that arrival-day reflex. It offers a chute-side blood test that returns a white blood cell count and differential in about two minutes [Advanced Animal Diagnostics website].
The company's lead product for beef is QScout BLD. This is a cartridge-based assay that lets a crew sort animals into treat and do-not-treat groups based on their actual immune signal rather than a herd-wide assumption.
In a feedlot trial the company has publicized, selectively treating cattle on QScout BLD results produced an 87% reduction in antibiotic use on arrival. The company estimates savings of $148,000 to $218,000 per 10,000 head at $17 to $25 per treatment [PR Newswire].
A separate Oklahoma backgrounder field test showed antibiotic use cut nearly in half on arrival with no significant difference in outcomes through 42 days [Advanced Animal Diagnostics website]. These are company-cited figures rather than peer-reviewed publications. Readers should weigh them as such, but the direction of the data is consistent across deployments.
The bet
AAD sells to two adjacent customers with the same underlying technology. On the beef side, the buyer is the feedlot or backgrounding operation trying to protect margins and meet retailer pressure on antibiotic stewardship.
On the dairy side, the product is QScout MLD, a test for subclinical mastitis in dairy cows. Used as part of a selective dry cow therapy protocol, the company reports a 47% reduction in antibiotic use for cows and 59% for quarters at dryoff [Advanced Animal Diagnostics website].
At Son-Bow Farms, QScout MLD was used to reduce somatic cell counts in heifers. Average milk production rose by 6 pounds per cow [Agweb].
The distribution wedge for the dairy product runs through Zoetis, the largest animal health company in the world. AAD has a license and commercialization agreement with Zoetis to distribute QScout MLD internationally outside the United States [PR Newswire]. The partnership covers marketing of the test for detecting subclinical mastitis and improving milk quality [North Carolina Biotechnology Center].
For a small diagnostics company, riding a Zoetis sales force into international dairy markets is a meaningful shortcut. It avoids the years it would otherwise take to build a direct field presence.
Why it could matter
The macro setup for on-farm diagnostics is unusually favorable. Regulators on both sides of the Atlantic have been tightening the screws on prophylactic antibiotic use in food animals.
The FDA's Guidance for Industry #213 ended the use of medically important antibiotics for growth promotion in 2017. The EMA's 2022 restrictions on veterinary antimicrobials reserved certain classes for human use only.
Retailers from McDonald's to Tyson have set their own stewardship targets. A test that lets a producer document selective treatment, with a paper trail, fits squarely into where the rules and the buyers are heading.
The investor syndicate reflects that thesis. AAD has raised roughly $40.5 million in disclosed funding, including a $15 million Series C [PR Newswire]. Investors include Novartis Venture Fund, Cultivian, Intersouth Partners, Middleland Capital, LabCorp, Alexandria Venture Investments, Murphy Family Ventures, and Mountain Group Partners.
The presence of LabCorp on the cap table is notable. The diagnostics giant rarely shows up on agtech rounds. Its involvement hints at the company's longer-term ambition in human point-of-care hematology.
There a related product, QScout RLD, reports a white blood cell count and differential in about two minutes from a drop of blood [Advanced Animal Diagnostics website].
QScout BLD feedlot trial, antibiotic reduction on arrival | 87 | %
QScout MLD selective dry cow therapy, cow-level reduction | 47 | %
QScout MLD selective dry cow therapy, quarter-level reduction | 59 | %
Oklahoma backgrounder field test, arrival antibiotic reduction | 50 | %
The team and traction
Co-founder Rudy Rodriguez brings more than 40 years in medical device development. He holds a BS in Electrical Engineering from the University of Miami and an MS in Biomedical Engineering from George Washington University [The Org, 2026].
Joy Parr Drach, also a co-founder, serves as president and CEO [Advanced Animal Diagnostics website]. The technical bench includes Norah Bate, who has worked as technical lead on reagent formulation and the QScout cell identification technology [LinkedIn].
The product family now spans three SKUs (BLD for beef, MLD for dairy, RLD for human point-of-care). All are built on the same underlying cell-counting platform. This is the kind of architectural reuse that keeps R&D costs in check as the company addresses different markets.
What bears say, what bulls answer
The most credible concern is evidentiary. The headline efficacy numbers come from company-published trials and field tests rather than peer-reviewed journals.
Competitors in veterinary diagnostics, including incumbents with established feedlot relationships, will press that point with skeptical buyers.
The bulls' answer, supported by the cited record, is that AAD has moved past pilot stage into a commercial distribution agreement with Zoetis [PR Newswire]. It has named on-farm deployments such as Son-Bow Farms [Agweb].
A test that a global animal health company is willing to put its sales force behind is one that has already cleared a meaningful internal diligence bar. This holds even before independent academic publication catches up.
What to watch
The next 12 months should clarify three things. First, whether the Zoetis-led international rollout of QScout MLD produces disclosed adoption numbers in European and Latin American dairy markets, where regulatory pressure on antibiotics is highest.
Second, whether AAD or its sister effort Ad Astra Diagnostics, which has received 510(k) clearance for a QScout hematology analyzer in human health [Advanced Animal Diagnostics website], converts that clearance into a clinical foothold.
Third, whether the company files for a follow-on round to fund commercial expansion now that the product portfolio is in market.
The disease states are real. The regulatory wind is at the company's back. The standard of care today (mass metaphylaxis on arrival, blanket dry cow therapy at dryoff) is exactly the kind of practice that a credible chute-side test can displace one cohort at a time.
Pulse Raman, Health and Bio Correspondent